Department of Pathology, Royal Infirmary of Edinburgh, Edinburgh, UK.
J Clin Pathol. 2011 Dec;64(12):1136-8. doi: 10.1136/jcp.2011.090571. Epub 2011 May 23.
Morphological sub-classification of non-small cell carcinoma in small biopsy specimens presents difficulties for pathologists and recent advances in chemotherapy have resulted in increased pressure to more robustly differentiate between squamous carcinoma and adenocarcinoma. The results of audits examining classification of non-small cell lung carcinoma by pathologists working in a specialist team within a regional centre and the effect of introducing adjunct immunohistochemistry into the reporting pathway are presented. It is concluded that the use of a limited immunohistochemical panel substantially reduces the number of cases when a specific cell type cannot be identified or 'favoured' (34% to 6%) and that the classification obtained correlates well with that found in subsequent resection specimens. In addition the introduction of immunohistochemistry substantially reduces the variability in reporting practice between pathologists.
在小活检标本中对非小细胞癌进行形态学亚分类对病理学家来说存在困难，而最近化疗的进展导致需要更有力地区分鳞状细胞癌和腺癌。本文介绍了在区域中心的一个专业团队中工作的病理学家对非小细胞肺癌分类进行审核的结果，以及引入辅助免疫组织化学检查报告途径的效果。结论是，使用有限的免疫组织化学组合可以大大减少无法确定或“倾向”特定细胞类型的病例数量（从 34%降至 6%），并且获得的分类与随后的切除标本中的分类很好地相关。此外，免疫组织化学的引入大大减少了病理学家报告实践之间的变异性。
